Flixabi is available in Germany, the UK, and the Netherlands, with launch in three additional countries expected in the fourth quarter. Bottom Line While Biogen's third quarter results were good, the slowdown in the overall MS market in the U.S. is concerning – Biogen said that the market witnessed a 2% decline in commercial patients compared to the third quarter of 2015. With the MS market getting more crowded and growth slowing down, it makes sense for Biogen to focus on its pipeline and add assets to its product portfolio.